"Common genetic variants in candidate genes and risk of familial lymphoid malignancies"
The Food and Drug Administration (FDA) has approved Eli Lillys Foundayo (orforglipron), a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, which offers a noninjectable option for weight management
Our results showed that exposure to fullerenols at 10, 30 and 50 g/mL dramatically attenuated CYP3A4 mRNA and protein expression in HTR-8/SVneo cells, and the levels of ER mRNA and protein were also lowered in cells exposed to fullerenols at 50 g/mL
Key Research Areas for FOXO4-DRI FOXO4p53 protein-protein interaction disruption assays co-immunoprecipitation (CO-IP) and competitive binding studies Senescent cell identification and selective elimination assays SA--galactosidase, p16, p21, p53 staining combined with FOXO4-DRI apoptosis induction p53 TAD2 binding, nuclear exclusion, and mitochondrial translocation studies phospho-p53 (Ser15) pathway research BAX/BCL-2/Caspase-3 intrinsic apoptosis pathway investigations in senescent cell models SASP (Senescence-Associated Secretory Phenotype) characterisation and suppression IL-6, IL-8, MMP, VEGF, CXCL2/3 pathway studies Tissue-specific senescent cell biology fibroblasts, endothelial cells, Leydig cells, chondrocytes, epithelial cells Vascular ageing pathway research endothelial cell senescence, aortic function, and ROS/oxidative stress studies Senescent Leydig cell and male reproductive ageing models FOXO4 nuclear translocation and testosterone synthesis pathway research Chondrocyte senescence and cartilage biology senescent cell removal and chondrogenic potential restoration studies Keloid and pathological scar biology senescent fibroblast elimination and SASP suppression in fibrotic tissue models Senescent cancer cell elimination FOXO4-DRI as a senolytic tool in oncology research models Comparative senolytic research FOXO4-DRI vs
